Journal
CANCER
Volume 124, Issue 24, Pages 4592-4596Publisher
WILEY
DOI: 10.1002/cncr.31681
Keywords
-
Categories
Funding
- National Institutes of Health/National Cancer Institute [P50 CA196530-01]
- Department of Defense Lung Cancer Research Program Career Development Award
Ask authors/readers for more resources
Recent trials have demonstrated that the addition of a programmed cell death protein 1 inhibitor to chemotherapy in the first-line setting in patients with metastatic squamous or nonsquamous non-small cell lung cancer improves survival compared with chemotherapy alone. These findings provide a new treatment option for patients with newly diagnosed, advanced non-small cell lung cancer, regardless of tumor histology or programmed death-ligand 1 expression, thereby representing a major advancement in the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available